Placebo-Controlled Confirmatory Study of Galantamine(R113675) for Alzheiner Type Dementia.

Trial Profile

Placebo-Controlled Confirmatory Study of Galantamine(R113675) for Alzheiner Type Dementia.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2013

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 30 Apr 2013 Actual initiation date changed from Jan 2006 to Feb 2007, as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Actual number of patients changed from 997 to 580 as reported by ClinicalTrials.gov.
    • 10 Sep 2009 Actual patient number (997) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top